Clinicopathologic and survival patterns among prostate carcinosarcoma patients in the U.S.

An analysis of SEER database

Authors

  • Asad Ullah Texas Tech University Health Sciences Center
  • Naema Daino Medical College of Georgia
  • Abdul Qahar Khan Yasinzai Bolan Medical College
  • Kue Tylor Lee Medical College of Georgia
  • Amir Humza Sohail University of New Mexico Medical Center
  • Aman Goyal Department of Internal Medicine, Seth GS Medical College and KEM Hospital, Mumbai, India
  • Abdul Waheed Department of Surgery, San Joaquin General Hospital, French Camp, CA 95231, USA,
  • Asif Iqbal University of South Alabama
  • Nabin R. Karki Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA

DOI:

https://doi.org/10.5489/cuaj.8769

Keywords:

Prostatic carcinosarcoma, SEER, Poorly differentiated, Metastasis

Abstract

INTRODUCTION: Prostatic carcinosarcoma comprises <1% of all prostate neoplasms. The literature on this disease is limited to a few case studies, primarily due to the rarity of this malignancy. We aimed to investigate the demographic, clinical, and histologic factors, prognosis, and survival of prostatic carcinosarcoma.

METHODS: The Surveillance, Epidemiology, and End Results (SEER) database was used to identify patients with prostatic carcinosarcoma from 2000–2018. Demographic and clinical data, including age, race, sex, tumor grade, stage, tumor size, lymph node status, metastasis, and treatment modalities, were recorded.

RESULTS: Patients with prostatic carcinosarcoma had a median age of 72 years at diagnosis, most cases among White individuals (93%). When reported, the histologic grade comprised moderately differentiated (3.3%), poorly differentiated (56.7%), and undifferentiated/anaplastic (40%) subtypes. In patients with reported data, tumor size varied between 2–5 cm (15.8%) and >5 cm (84.2%). Distant metastasis most commonly occurred in the liver (12.5%) and lung (12.5%), followed by the bone (8.3%). The most common treatment performed was surgery with radiation (32.4%). The five-year overall survival was 11.9%.

CONCLUSIONS: Prostatic carcinosarcoma affects men in the seventh decade of life. Regional and distant tumor stage is considered an indicator of survival. Prostate carcinosarcoma is rare; due to its aggressive nature, a deeper understanding, and an improved personalized therapeutic approach are necessary for improving patient outcomes in this challenging arena of oncology.

Downloads

Download data is not yet available.

Downloads

Published

2024-06-17

How to Cite

Ullah, A., Daino, N., Yasinzai, A. Q. K., Lee, K. T., Sohail, A. H., Goyal, A., … Karki, N. R. (2024). Clinicopathologic and survival patterns among prostate carcinosarcoma patients in the U.S.: An analysis of SEER database. Canadian Urological Association Journal, 18(11), E334–8. https://doi.org/10.5489/cuaj.8769

Issue

Vol. 18 No. 11 (2024): CUAJ November

Section

Original Research

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.